Informed Consent and Adverse events [GxP / QC / QA]

posted by cakhatri – India, 2012-10-09 09:38 (4995 d 09:06 ago) – Posting: # 9349
Views: 5,750

(edited on 2012-10-09 10:08)

Dear Yogesh,

If I were to decide, I would list all possible AEs with their percentage in the Protocol and ICF, because on ehtical grounds a company conducting trials on healthy human subjects is supposed to provide every minute details that is available for the product, and if not described in ICF and with even minor chances of occurrence during the study may lead to gross ethical negligence.

Opinion from other members welcome

Regards
Chirag


Edit: Full quote removed. Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
97 visitors (0 registered, 97 guests [including 23 identified bots]).
Forum time: 18:45 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5